LW402

DRUG2 trials

Sponsors

Shanghai Longwood Biopharmaceuticals Co., Ltd.

Conditions

Atopic Dermatitis (AD)Moderate to Severe Atopic Dermatitis

Phase 2

Study of LW402 in Moderate-to-Severe Atopic Dermatitis

CompletedNCT07186387

Shanghai Longwood Biopharmaceuticals Co., Ltd.Atopic Dermatitis (AD)

Start: 2023-05-11End: 2025-02-13Updated: 2025-10-02

Phase 3

Evaluation of the Efficacy and Safety of Oral LW402 Tablets for the Treatment of Patients With Moderate-to-Severe Atopic Dermatitis

RecruitingNCT07370909

Shanghai Longwood Biopharmaceuticals Co., Ltd.Moderate to Severe Atopic Dermatitis

Start: 2026-03-03End: 2028-12-31Target: 480Updated: 2026-08-27